Safety Follow-up Study for Subjects With Agitation Associated With Dementia of the Alzheimer's Type Who Previously Participated in a Double-blind Trial of Brexpiprazole or Placebo
A 2-Month, Observational, Rollover Trial to Evaluate the Safety of Subjects With Agitation Associated With Dementia of the Alzheimer's Type Who Were Previously Treated With Brexpiprazole (OPC 34712) or Placebo in a Phase 3, Double-blind Trial
1 other identifier
observational
450
12 countries
84
Brief Summary
To follow-up on the safety of subjects who were previously treated in a double-blind trial of brexpiprazole.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jun 2014
Typical duration for all trials
84 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
June 1, 2014
CompletedFirst Submitted
Initial submission to the registry
July 15, 2014
CompletedFirst Posted
Study publicly available on registry
July 17, 2014
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 1, 2017
CompletedStudy Completion
Last participant's last visit for all outcomes
May 1, 2017
CompletedApril 30, 2018
April 1, 2018
2.9 years
July 15, 2014
April 27, 2018
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
Adverse Events (AEs)
Baseline to Month 2/Early Termination
Mini-Mental State Examination (MMSE) score
Baseline to Month 2/Early Termination
Eligibility Criteria
Subjects must have completed a previous double-blind trial of brexpiprazole or placebo; neither drug or placebo will be administered in the trial
You may qualify if:
- The investigator must assess the capacity of the subject to provide informed consent prior to enrollment and throughout the trial.
- Male and female subjects who completed both the 12-week double-blind treatment period and the 30-day safety follow-up visit of the previous brexpiprazole trial.
- Subject has an identified caregiver who is usually assigned to care for the subject on a regular basis, has sufficient contact to describe the subject's symptoms, and has direct observation of the subject's behavior.
- Subject is able to comply with the protocol requirements.
- Subjects who, in the opinion of the investigator, medical monitor, or sponsor should not participate in the trial.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (84)
Unknown Facility
Tuscaloosa, Alabama, 35404, United States
Unknown Facility
Costa Mesa, California, 92626, United States
Unknown Facility
Lakewood, California, 90805, United States
Unknown Facility
Orange, California, 92868, United States
Unknown Facility
Redlands, California, 92373, United States
Unknown Facility
Bradenton, Florida, 34205, United States
Unknown Facility
Hialeah, Florida, 33012, United States
Unknown Facility
Hialeah, Florida, 33018, United States
Unknown Facility
Miami, Florida, 33122, United States
Unknown Facility
Miami, Florida, 33126, United States
Unknown Facility
Miami, Florida, 33137, United States
Unknown Facility
Miami, Florida, 33175, United States
Unknown Facility
Miami Springs, Florida, 33166, United States
Unknown Facility
North Miami, Florida, 33161, United States
Unknown Facility
Orange City, Florida, 32763, United States
Unknown Facility
Sarasota, Florida, 34239, United States
Unknown Facility
Atlanta, Georgia, 30331, United States
Unknown Facility
Suwanee, Georgia, 30024, United States
Unknown Facility
Quincy, Massachusetts, 02169, United States
Unknown Facility
St Louis, Missouri, 63128, United States
Unknown Facility
Toms River, New Jersey, 08755, United States
Unknown Facility
Brooklyn, New York, 11214, United States
Unknown Facility
New Hyde Park, New York, 11040, United States
Unknown Facility
Charlotte, North Carolina, 28270, United States
Unknown Facility
Hickory, North Carolina, 28601, United States
Unknown Facility
Raleigh, North Carolina, 27609, United States
Unknown Facility
Dallas, Texas, 75243, United States
Unknown Facility
Waukesha, Wisconsin, 53188, United States
Unknown Facility
Burgas, 8000, Bulgaria
Unknown Facility
Kardzhali, 6600, Bulgaria
Unknown Facility
Rousse, 7003, Bulgaria
Unknown Facility
Sofia, 1113, Bulgaria
Unknown Facility
Sofia, 1431, Bulgaria
Unknown Facility
Varna, 9020, Bulgaria
Unknown Facility
Veliko Tarnovo, 5000, Bulgaria
Unknown Facility
Penticton, British Columbia, V2A 4M4, Canada
Unknown Facility
Kentville, Nova Scotia, B4N 4K9, Canada
Unknown Facility
Zagreb, 10000, Croatia
Unknown Facility
Zagreb, 10090, Croatia
Unknown Facility
Bourg N Bresse, 01012, France
Unknown Facility
Douai, 59500, France
Unknown Facility
Élancourt, 78990, France
Unknown Facility
Toulouse, 31059, France
Unknown Facility
Mittweida, Saxony, 9648, Germany
Unknown Facility
Berlin, 12209, Germany
Unknown Facility
Bochum, 44791, Germany
Unknown Facility
Cologne, 50935, Germany
Unknown Facility
Westerstede, 26655, Germany
Unknown Facility
Saint Petersburg, 190000, Russia
Unknown Facility
Saint Petersburg, 190005, Russia
Unknown Facility
Saint Petersburg, 191040, Russia
Unknown Facility
Saint Petersburg, 191119, Russia
Unknown Facility
Saint Petersburg, 192019, Russia
Unknown Facility
Saint Petersburg, 195176, Russia
Unknown Facility
Saint Petersburg, 197341, Russia
Unknown Facility
Saint Petersburg, 198510, Russia
Unknown Facility
Samara, 443016, Russia
Unknown Facility
Saratov, 410060, Russia
Unknown Facility
Tonnelniy, 357034, Russia
Unknown Facility
Yekaterinburg, 620030, Russia
Unknown Facility
Belgrade, 11000, Serbia
Unknown Facility
Kovin, 26220, Serbia
Unknown Facility
Kragujevac, 34000, Serbia
Unknown Facility
Niš, 18000, Serbia
Unknown Facility
Novi Kneževac, 23330, Serbia
Unknown Facility
Novi Sad, 21000, Serbia
Unknown Facility
Ljubljana, 1000, Slovenia
Unknown Facility
Maribor, 2000, Slovenia
Unknown Facility
Šempeter pri Gorici, 5290, Slovenia
Unknown Facility
Pamplona, 31014, Spain
Unknown Facility
Salamanca, 37004, Spain
Unknown Facility
Valencia, 46010, Spain
Unknown Facility
Valencia, 46026, Spain
Unknown Facility
Zamora, 49021, Spain
Unknown Facility
Kharkiv, 61068, Ukraine
Unknown Facility
Kherson, 73488, Ukraine
Unknown Facility
Kiev, 04080, Ukraine
Unknown Facility
Kiev, 04114, Ukraine
Unknown Facility
Lviv, 79021, Ukraine
Unknown Facility
Odesa, 35006, Ukraine
Unknown Facility
Odesa, 67513, Ukraine
Unknown Facility
Poltava, 36013, Ukraine
Unknown Facility
Vinnytsia, 21005, Ukraine
Unknown Facility
Torpoint, PL11 2TB, United Kingdom
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Eva Kohegyi, MD, MS
Otsuka Pharmaceutical Development & Commercialization, Inc.
Study Design
- Study Type
- observational
- Observational Model
- OTHER
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
July 15, 2014
First Posted
July 17, 2014
Study Start
June 1, 2014
Primary Completion
May 1, 2017
Study Completion
May 1, 2017
Last Updated
April 30, 2018
Record last verified: 2018-04